ProShare Advisors’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-18,904
| Closed | -$51K | – | 1864 |
|
|
2022
Q1 | $51K | Sell |
18,904
-4,418
| -19% | -$11.9K | ﹤0.01% | 2112 |
|
|
2021
Q4 | $102K | Buy |
23,322
+1,090
| +5% | +$4.77K | ﹤0.01% | 2203 |
|
|
2021
Q3 | $113K | Sell |
22,232
-6,276
| -22% | -$31.9K | ﹤0.01% | 1899 |
|
|
2021
Q2 | $180K | Buy |
28,508
+3,100
| +12% | +$19.6K | ﹤0.01% | 2173 |
|
|
2021
Q1 | $196K | Buy |
25,408
+8,270
| +48% | +$63.8K | ﹤0.01% | 2050 |
|
|
2020
Q4 | $112K | Buy |
17,138
+4,157
| +32% | +$27.2K | ﹤0.01% | 1975 |
|
|
2020
Q3 | $86K | Sell |
12,981
-494
| -4% | -$3.27K | ﹤0.01% | 1538 |
|
|
2020
Q2 | $112K | Buy |
+13,475
| New | +$112K | ﹤0.01% | 1556 |
|
|
2020
Q1 | – | Sell |
-15,930
| Closed | -$132K | – | 1259 |
|
|
2019
Q4 | $132K | Sell |
15,930
-1,435
| -8% | -$11.9K | ﹤0.01% | 1659 |
|
|
2019
Q3 | $128K | Sell |
17,365
-575
| -3% | -$4.24K | ﹤0.01% | 1519 |
|
|
2019
Q2 | $201K | Sell |
17,940
-2,223
| -11% | -$24.9K | ﹤0.01% | 1438 |
|
|
2019
Q1 | $217K | Buy |
20,163
+220
| +1% | +$2.37K | ﹤0.01% | 1426 |
|
|
2018
Q4 | $301K | Sell |
19,943
-3,840
| -16% | -$58K | ﹤0.01% | 1150 |
|
|
2018
Q3 | $440K | Buy |
23,783
+2,332
| +11% | +$43.1K | ﹤0.01% | 1168 |
|
|
2018
Q2 | $490K | Sell |
21,451
-21
| -0.1% | -$480 | ﹤0.01% | 1131 |
|
|
2018
Q1 | $611K | Sell |
21,472
-3,534
| -14% | -$101K | ﹤0.01% | 1026 |
|
|
2017
Q4 | $528K | Buy |
+25,006
| New | +$528K | ﹤0.01% | 1102 |
|